Context Therapeutics (CNTX) Earnings Date, Estimates & Call Transcripts $1.16 +0.01 (+0.87%) (As of 01:18 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Context Therapeutics Latest Earnings SummaryActual EPS (Nov. 6) -$0.22 Missed By -$0.11 Consensus EPS (Nov. 6) -$0.11 Context Therapeutics released Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.22, which missed the consensus estimate of -$0.11 by $0.11. With a trailing EPS of -$0.91, Context Therapeutics' earnings are expected to grow next year, from ($0.51) to ($0.31) per share. Get Context Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCNTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CNTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Context Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.23-$0.23-$0.23Q2 20241-$0.27-$0.27-$0.27Q3 20242-$0.28-$0.16-$0.22Q4 20242-$0.31-$0.04-$0.18FY 20246($1.09)($0.70)($0.90) Context Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/6/2024--$0.11-$0.22 -$0.11-$0.22--8/7/2024--$0.08-$0.04+$0.04-$0.04--5/8/2024Q1 2024-$0.38-$0.23+$0.15-$0.23--3/21/2024Q4 2023-$0.35-$0.42 -$0.07-$0.42--11/9/2023Q3 2023-$0.30-$0.37 -$0.07-$0.37--8/9/2023Q2 2023-$0.20-$0.31 -$0.11-$0.31-- Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/10/2023Q1 2023-$0.19-$0.40 -$0.21-$0.40--3/22/2023Q4 2022-$0.30-$0.22+$0.08-$0.22-- Context Therapeutics Earnings - Frequently Asked Questions When did Context Therapeutics announce their last quarterly earnings? Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earning data on Wednesday, November 6, 2024. Learn more on CNTX's earnings history. Did Context Therapeutics beat their earnings estimates last quarter? In the previous quarter, Context Therapeutics (NASDAQ:CNTX) missed the analysts' consensus estimate of ($0.11) by $0.11 with a reported earnings per share (EPS) of ($0.22). Learn more on analysts' earnings estimate vs. CNTX's actual earnings. How much profit does Context Therapeutics generate each year? Context Therapeutics (NASDAQ:CNTX) has a recorded net income of -$23.96 million. CNTX has generated -$0.91 earnings per share over the last four quarters. What is Context Therapeutics's EPS forecast for next year? Context Therapeutics's earnings are expected to grow from ($0.51) per share to ($0.31) per share in the next year. More Earnings Resources from MarketBeat Related Companies CCCC Earnings Results ATYR Earnings Results CADL Earnings Results AMLX Earnings Results CMPS Earnings Results FHTX Earnings Results AVIR Earnings Results FDMT Earnings Results CMRX Earnings Results ITOS Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. This page (NASDAQ:CNTX) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners$19 for a FULL YEAR of stock picks?!We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? ...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
